The latest announcement is out from Opthea Limited ( (AU:OPT) ).
Opthea Limited has successfully completed its drug product Process Performance Qualification (PPQ) campaign for sozinibercept, marking a significant step towards a potential biologics license application (BLA) filing in the first half of 2026. The successful production of three commercial-scale batches demonstrates Opthea’s capability to manufacture quality drug products at scale, potentially positioning sozinibercept as a groundbreaking therapy for wet AMD, which could have significant implications for the company’s market presence and stakeholders.
More about Opthea Limited
Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening eye diseases, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Their lead product, sozinibercept, is a first-in-class VEGF-C/D inhibitor aimed at improving vision in wet AMD patients.
YTD Price Performance: 9.09%
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $757.7M
See more data about OPT stock on TipRanks’ Stock Analysis page.